Moleculin Biotech, Inc.
MBRXHealthcare|Biotechnology|US
$8.70
-0.03 (-0.34%)
DCF Value
$90.32
Tangible Book / Share
$1.55
Cash / Share
$25.57
Financials
Financial Snapshot
Market Cap
$8.9M
Enterprise Value
$1.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$30.3M
Cash & Investments
$7.3M
Net Cash
$7.0M
Free Cash Flow (TTM)
-$25.4M
Operating CF (TTM)
-$25.4M
Debt/Equity
0.03
Cash Runway & Burn Rate
Cash on Hand
$7.3M
Quarterly Burn
$6.3M
Monthly Burn
$2.1M
Est. Runway
~1.1 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.0M | $7.7M | $7.1M | $10.7M | $15.2M | $70.9M | $43.1M | $23.6M | $4.3M | $8.9M | $7.3M | |
| Operating Cash Flow | -$3.8M | -$7.3M | -$12.2M | -$17.2M | -$17.8M | -$19.0M | -$27.6M | -$24.1M | -$23.9M | -$22.7M | -$25.4M | |
| Free Cash Flow | -$3.8M | -$7.4M | -$12.6M | -$17.3M | -$18.1M | -$19.0M | -$27.7M | -$24.2M | -$23.9M | -$22.7M | -$25.4M | |
| Capital Expenditure | -$21.5K | -$28.0K | -$417.0K | -$52.0K | -$376.0K | -$19.0K | -$67.0K | -$124.0K | -$13.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $8.9M | $10.1M | $12.0M | $20.9M | $22.5M | $74.7M | -$23.0K | $4.7M | $4.6M | $27.3M | $25.1M |
R&D Spending
R&D (TTM)
$19.7M
R&D Intensity
—
R&D Growth vs Prior
+23.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.5M | $4.5M | $9.7M | $11.0M | $12.8M | $14.4M | $19.0M | $19.5M | $17.7M | $15.9M | $19.7M | |
| SG&A | $2.4M | $4.1M | $5.3M | $6.3M | $6.8M | $8.4M | $11.5M | $10.0M | $8.8M | $9.1M | $9.1M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $6.2K | $18.0K | $68.0K | $185.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $90.0K | $8.0K | |
| Gross Profit | -$6.2K | -$18.0K | -$68.0K | -$185.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$90.0K | -$8.0K | |
| R&D | $1.5M | $4.5M | $9.7M | $11.0M | $12.8M | $14.4M | $19.0M | $19.5M | $17.7M | $15.9M | $19.7M | |
| SG&A | $2.4M | $4.1M | $5.3M | $6.3M | $6.8M | $8.4M | $11.5M | $10.0M | $8.8M | $9.1M | $9.1M | |
| Operating Income | -$3.9M | -$8.7M | -$15.0M | -$17.5M | -$19.7M | -$23.0M | -$30.6M | -$29.6M | -$26.6M | -$25.1M | -$28.9M | |
| Interest Expense | $43.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $78.0K | |
| Pretax Income | -$3.9M | -$9.8M | -$11.9M | -$13.4M | -$17.4M | -$15.9M | -$29.0M | -$29.8M | -$21.8M | -$33.6M | -$30.3M | |
| Net Income | -$3.9M | -$9.8M | -$11.9M | -$13.2M | -$17.4M | -$15.9M | -$29.0M | -$29.8M | -$21.8M | -$33.6M | -$30.3M | |
| EPS (Diluted) | -18000.00 | -23761.40 | -20630.80 | -14592.60 | -13220.00 | -4435.40 | -7610.20 | -7534.20 | -3782.80 | -568.40 | -342.60 | |
| EBITDA | -$3.9M | -$8.6M | -$15.0M | -$13.2M | -$19.5M | -$15.7M | -$28.9M | -$29.6M | -$21.6M | -$33.5M | -$30.2M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.28 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.0M | $7.7M | $7.1M | $10.7M | $15.2M | $70.9M | $43.1M | $23.6M | $4.3M | $8.9M | $7.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $5.2M | $8.3M | $8.0M | $13.5M | $17.2M | $72.5M | $45.6M | $26.3M | $5.2M | $9.7M | $8.7M | |
| Total Assets | $16.4M | $19.5M | $19.6M | $25.2M | $29.2M | $84.1M | $57.4M | $38.2M | $16.9M | $22.1M | $21.1M | |
| Total Current Liabilities | $1.3M | $2.2M | $3.9M | $3.6M | $2.9M | $3.6M | $4.8M | $6.8M | $5.4M | $6.9M | $9.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.4M | $2.4M | $5.3M | $9.7M | $11.3M | $5.1M | $5.2M | $12.1M | $10.9M | $7.1M | $9.5M | |
| Stockholders' Equity | $15.0M | $17.1M | $14.3M | $15.6M | $17.9M | $79.0M | $52.2M | $26.1M | $6.0M | $15.0M | $11.6M | |
| Retained Earnings | -$4.7M | -$14.5M | -$26.4M | -$39.6M | -$56.9M | -$72.8M | -$101.8M | -$131.6M | -$153.4M | -$206.0M | -$226.5M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.8M | -$7.3M | -$12.2M | -$17.2M | -$17.8M | -$19.0M | -$27.6M | -$24.1M | -$23.9M | -$22.7M | -$25.4M | |
| Capital Expenditure | -$21.5K | -$28.0K | -$417.0K | -$52.0K | -$376.0K | -$19.0K | -$67.0K | -$124.0K | -$13.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$3.8M | -$7.4M | -$12.6M | -$17.3M | -$18.1M | -$19.0M | -$27.7M | -$24.2M | -$23.9M | -$22.7M | -$25.4M | |
| Investing Cash Flow | -$121.1K | -$28.0K | -$417.0K | -$51.0K | -$374.0K | -$19.0K | -$67.0K | -$124.0K | -$13.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $8.9M | $10.1M | $12.0M | $20.9M | $22.5M | $74.7M | -$23.0K | $4.7M | $4.6M | $27.3M | $25.1M | |
| Issuance of Stock | $9.2M | $6.1M | $12.0M | $19.3M | $22.6M | $74.7M | $0.00 | $4.2M | $4.7M | $27.3M | $25.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$23.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$304.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $411.5K | $707.0K | $1.1M | $1.5M | $1.7M | $2.4M | $2.3M | $2.0M | $1.7M | $1.7M | $1.3M | |
| Net Change in Cash | $5.0M | $2.7M | -$580.0K | $3.6M | $4.4M | $55.7M | -$27.8M | -$19.6M | -$19.3M | $4.6M | -$295.0K |
Dilution Tracker
Shares outstanding grew 4410.9% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+4410.9%
Stock Issuance (TTM)
$25.1M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.28 | |
| Change vs Prior % | — | 89.4% | 39.5% | 57.1% | 45.1% | 172.9% | 6.4% | 3.6% | 74.3% | 760.1% | 379.6% | |
| Stock Issuance | $9.2M | $6.1M | $12.0M | $19.3M | $22.6M | $74.7M | $0.00 | $4.2M | $4.7M | $27.3M | $25.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$23.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $411.5K | $707.0K | $1.1M | $1.5M | $1.7M | $2.4M | $2.3M | $2.0M | $1.7M | $1.7M | $1.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -26.2% | -57.3% | -83.2% | -84.8% | -97.0% | -20.1% | -55.6% | -114.2% | -364.0% | -223.6% | -816.6% | |
| ROA % | -24.0% | -50.3% | -60.6% | -52.3% | -59.5% | -18.9% | -50.5% | -77.9% | -128.6% | -151.7% | -143.8% | |
| ROIC % | -25.3% | -50.1% | -95.7% | -79.1% | -74.9% | -28.5% | -58.1% | -94.1% | -228.0% | -162.9% | -242.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -192.1% | -277.8% | -172.1% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -426.0% | -122.8% | -73.6% | -16.6% | -12.7% | -16.3% | -33.4% | 3.3% | 10.1% | 5.8% | |
| Net Income | -424.7% | -149.7% | -21.1% | -11.2% | -31.4% | 8.4% | -82.6% | -2.6% | 26.9% | -54.2% | |
| EPS (Diluted) | -662.9% | -32.0% | 13.2% | 29.3% | 9.4% | 66.4% | -71.6% | 1.0% | 49.8% | 85.0% | |
| Operating Cash Flow | -789.0% | -94.5% | -66.6% | -40.9% | -3.3% | -6.6% | -45.8% | 12.8% | 1.0% | 4.7% | |
| Free Cash Flow | -794.0% | -94.2% | -71.7% | -36.7% | -5.2% | -4.5% | -46.1% | 12.6% | 1.4% | 4.8% | |
| R&D Expense | 474.3% | 203.9% | 114.0% | 13.2% | 15.8% | 13.0% | 31.6% | 2.7% | -9.0% | -10.4% | |
| SG&A Expense | 398.4% | 71.7% | 29.5% | 19.4% | 7.3% | 23.6% | 37.6% | -13.2% | -12.3% | 3.8% | |
| Total Assets | 58256.5% | 18.8% | 0.5% | 28.8% | 15.6% | 188.4% | -31.7% | -33.4% | -55.7% | 30.7% | |
| Book Value / Share | 3021.2% | -39.6% | -40.2% | -30.6% | -20.8% | 61.8% | -37.9% | -51.8% | -86.8% | -70.8% | |
| Debt | -34.1% | -100.0% | 0.0% | 0.0% | -26.9% | -42.6% | 183.6% | 27.3% | -16.7% | -24.9% | |
| Diluted Shares | -31.2% | 89.4% | 39.5% | 57.1% | 45.1% | 172.9% | 6.4% | 3.6% | 74.3% | 760.1% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.21
10Y Low / Med / High0.26 / 1.50 / 2.63
EV/EBITDAAt Loss
10Y Low / Med / High0.14 / 0.43 / 1.32
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$90.32
Tangible Book / Share
$1.55
Cash / Share
$25.57
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -5.70 | -3.52 | -2.27 | -2.82 | -2.71 | -3.15 | -1.04 | -0.85 | -0.22 | -0.12 | -0.03 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 1.50 | 2.02 | 1.89 | 2.39 | 2.63 | 0.63 | 0.58 | 0.98 | 0.98 | 0.26 | 0.21 | |
| EV/EBITDA | -4.55 | -3.11 | -1.33 | -2.03 | -1.65 | 1.32 | 0.43 | -0.08 | -0.09 | 0.14 | -0.06 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-19.25
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $71.4M | $42.0M | $87.0M |
| Net Income | -$3.9M | -$1.4M | -$1.6M |
| EPS | $-65.33 | $-23.40 | $-26.40 |
| # Analysts (EPS) | 2 | 2 | 2 |